WO2008062840A1 - Method for removing organic solvent - Google Patents
Method for removing organic solvent Download PDFInfo
- Publication number
- WO2008062840A1 WO2008062840A1 PCT/JP2007/072577 JP2007072577W WO2008062840A1 WO 2008062840 A1 WO2008062840 A1 WO 2008062840A1 JP 2007072577 W JP2007072577 W JP 2007072577W WO 2008062840 A1 WO2008062840 A1 WO 2008062840A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- organic solvent
- gelatin
- organic
- biopolymer
- solvent according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
- C08J7/02—Chemical treatment or coating of shaped articles made of macromolecular substances with solvents, e.g. swelling agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L89/00—Compositions of proteins; Compositions of derivatives thereof
- C08L89/04—Products derived from waste materials, e.g. horn, hoof or hair
- C08L89/06—Products derived from waste materials, e.g. horn, hoof or hair derived from leather or skin, e.g. gelatin
Definitions
- the present invention relates to a method for removing a residual organic solvent contained in a structure, and a structure made of gelatin or collagen in which the residual amount of an organic fluorine compound is reduced.
- 1,1,1,3,3,3-Hexafluoro-Organic fluorine compounds represented by 2-propanol (HFIP) and trifluoroethanol (TFE) contain collagen, gelatin, and protein. Dissolve. In Japanese Translation of PCT Publication No. 2002-531182, a matrix for tissue construction is prepared by dissolving the protein in HFIP and molding it.
- the electrospinning method has attracted attention as a technology that can easily produce submicron-scale fibers!
- a solution is injected while a voltage is applied to a polymer solution to form a fiber.
- the thickness of the fiber depends on the applied voltage, solution concentration, and spray distance.
- the membrane can be made as thick as a cloth, and a non-woven fabric with a submicron mesh can be produced. The application of this nonwoven fabric to space suits and protective clothing is being studied.
- HFIP is mainly used as a solvent for producing collagen or gelatin as a fibrous structure using the electrospinning method. Since HFIP and TFE have toxicity such as irritation, it is necessary to remove them after creating the structure, especially when used in medical applications.
- Structures made using the organic fluorine compounds are described as being capable of removing HFIP by vacuum drying with the force of natural drying or vacuum drying (Japanese Patent Publication No. 2002-531182). The determination of the solvent and the aggressive removal of the solvent are not discussed.
- the washing operation of the structure manufactured from HFIP is performed by using the force S and the HFIP contained in the structure described in JP 2002-531182, No. 2002-27283, etc. The purpose is to remove salt and proteins.
- Patent Document 1 Japanese Translation of Special Publication No. 2002-531182
- Patent Document 2 Special Table 2004-532802
- Patent Document 3 Japanese Patent Laid-Open No. 2004-321484
- Patent Document 4 Japanese Patent Laid-Open No. 2002-27283
- An object of the present invention is to provide an efficient method for removing the residual organic solvent inside the biopolymer structure, which has been a problem in the prior art.
- the present inventors have used an atmosphere of another solvent in the gas instead of a method such as vacuum or high heat, which is a usual solvent removal method. It has been found that the residual solvent can be removed efficiently. Furthermore, the present inventors have found that the residual organic solvent in the structure in the biopolymer can be removed by washing the structure of the biopolymer with water. Furthermore, the present inventors have found that the residual solvent can be efficiently removed by mixing a hydrophilic compound in the structure instead of the usual solvent removal means such as vacuum or high heat. That is, the technique can efficiently provide a technique for removing toxic organic solvents.
- a method for removing an organic solvent contained in a biopolymer structure from the structure under an atmosphere of a solvent different from the organic solvent comprising removing the organic solvent by placing the structure Is provided.
- the biopolymer is a protein.
- the protein is at least one selected from the group consisting of collagen, gelatin, albumin, laminin, casein, fiproin, fibrin, fibronectin, and vitronectin.
- the biopolymer is cross-linked.
- the solvent different from the organic solvent is a solvent compatible with the organic solvent.
- the solvent compatible with the organic solvent is water, alcohol or ketone.
- the sum of the ratio of the vapor pressure of the solvent other than the organic solvent to the saturated vapor pressure is
- the solvent other than the organic solvent is water, and the organic solvent is removed under an atmosphere having a humidity of 55% or more.
- the temperature for removing the organic solvent is 25 ° C to 200 ° C.
- the organic solvent to be removed is an organic fluorine compound.
- the organic fluorine compound is trifluoroethanol, 1,1,1,3,3,3 oxafluoro-2-propanol, hexafluoroacetone, trifluoroacetic acid, or pentafluoropropionic acid.
- the structure is made of gelatin or collagen produced using an organic fluorine compound, and the amount of the organic fluorine compound remaining in the structure is 0.1% or less.
- a composition comprising gelatin or collagen is provided.
- the thickness of the structure is 1 nm or more.
- the organic fluorine compound is trifluoroethanol, 1,1,1,3,3,3 oxafluoro-2-propanol, hexafluoroacetone, trifluoroacetic acid, or pentafluoropropionic acid.
- a method for removing an organic solvent contained in a biopolymer structure from the structure wherein the structure is a solution containing water as a main component.
- a method for removing an organic solvent characterized in that the organic solvent is removed by washing.
- the biopolymer is a protein, a polysaccharide and a derivative thereof.
- the biopolymer is a protein and its derivatives.
- the biopolymer is a protein.
- the protein includes at least one selected from the group consisting of collagen, gelatin, albumin, laminin, casein, fiproin, fibrin, fibronectin, and vitronectin.
- the protein is a protein derived from a human, cow, pig, or fish, or a recombinant protein.
- the polysaccharide is chitin, chitosan, hyaluronic acid, heparin, heparan sulfate, chondroitin sulfate.
- the biopolymer is cross-linked.
- the cross-linking of the biopolymer is performed using heat, light, a condensing agent, or an enzyme.
- the organic solvent to be removed is an organic fluorine compound.
- the organofluorine compound is 1,1,1,1,3,3,3-hexafluoro-2-propanol, trifluoroethanol, hexafluoroacetone, trifluoroacetic acid, or pentafluoropropionic acid. is there.
- a method for removing an organic solvent contained in a structure of a biopolymer from the structure comprising including a hydrophilic compound in the structure.
- a method for removing an organic solvent is provided.
- the biopolymer is a protein.
- the protein is at least one selected from the group consisting of collagen, gelatin, albumin, laminin, casein, fiproin, fibrin, fibronectin, and vitronectin.
- the biopolymer is cross-linked.
- the solubility of the hydrophilic compound in water is 1 mg / mL or more.
- the boiling point of the hydrophilic compound is 100 ° C or higher.
- the hydrophilic compound is a saccharide, salt, alcohol, carboxylic acid, ether And amines and amides.
- the hydrophilic compound is glycerol, ethylene glycol, propylene glycol, butylene glycol, polyethylene glycol, sodium chloride, lactose, sodium polyphosphate, sodium L-ascorbate.
- the organic solvent to be removed is an organic fluorine compound.
- the organofluorine compound is trifluoroethanol, 1,1,1,3,3,3 xafluoro-2-propanol, hexafluoroacetone, trifluoroacetic acid, or pentafluoropropionic acid.
- the organofluorine compound is trifluoroethanol or 1,1,1,3,3,3-hexafluoro-2-propanol.
- the method of the present invention it is possible to efficiently remove the residual solvent in the structure used during the manufacturing process.
- the method of the present invention unlike the method of removing impurities by immersing the structure in a solvent, the elution of the structure into the solvent minimizes deformation due to swelling, and the encapsulated compound does not flow out.
- the ability to remove residual solvent, which is a good solvent for encapsulated compounds, can be achieved.
- the first aspect of the present invention is a method for removing the organic solvent contained in a structure of a biopolymer from the force of the structure, and in an atmosphere of a solvent different from the organic solvent.
- the organic solvent is removed by placing the structure on the substrate.
- the solvent used in the gas is preferably water, alcohol or ketone, more preferably water or alcohol. More preferred is water, ethanol, or isopropanol. More preferred is water or ethanol. Most preferred is water.
- the solvent used in the gas may be one type of solvent or a mixed gas of two or more types of solvents.
- another criterion for selecting a solvent used in the gas is that the structure can be dissolved or swelled.
- the total ratio of the solvent to the saturated vapor pressure at the temperature in the gas is not particularly specified, but is preferably 55% or more. More preferably, it is 70% or more. Most preferably, it is 80% or more.
- the ratio of the vapor pressure of the solvent to the saturated vapor pressure is humidity. That is, when the solvent other than the organic solvent is water, the humidity is preferably 55% or more, more preferably 70% or more, and most preferably 80% or more.
- the saturated water vapor amount greatly varies depending on the temperature, the required humidity at the temperature at which the solvent is removed may vary.
- the gas temperature is not specified, but it is preferably 25 ° C or higher and 200 ° C or lower.
- the temperature of the system is a force S that varies greatly depending on the type of residual solvent and mixture, preferably a temperature just below the boiling point of the residual solvent.
- a second aspect of the method of the present invention is characterized in that the organic solvent is removed by washing the structure with a solution containing water as a main component.
- the solution mainly containing water used for cleaning may be pure water or an aqueous solution containing various additives.
- the compound that can be added as an aqueous solution include various inorganic salts, pH adjusters, and water-compatible solvents. More preferably, it is deionized water or an aqueous solution containing various inorganic salts. Most preferred is deionized water or a buffer solution.
- There is no special provision for the cleaning operation! / For example, the ability to immerse in a large amount of water or aqueous solution, or to spray water or aqueous solution.
- the temperature of the water or aqueous solution to be washed can be used as long as the water exists in solution.
- the temperature is preferably 0 ° C to 60 ° C. More preferably, it is 0 ° C to 40 ° C. Most preferably, it is 0 ° C to 30 ° C.
- a pH near neutral is preferable.
- pH 5-10. More preferably, the pH is 6-9.
- the optimum pH of the cleaning solvent depends on the acidity of the residual organic solvent.
- a weak alkali (7 to pH 9) is preferred.
- a solvent having a high basicity pKa> 15.7
- a weak acidity 5 to pH 7 is preferred.
- the organic solvent contained in the structure can be removed from the structure by drying the structure of the biopolymer.
- the ratio of the solvent in the gas with respect to the saturated vapor pressure at the time of drying is not particularly specified, but the solvent removal efficiency is improved by increasing the ratio.
- the ratio is 55% or more. More preferably, it is 70% or more. Most preferably, it is 80% or more.
- the ratio of the vapor pressure of the solvent to the saturated vapor pressure is humidity. That is, when the solvent other than the organic solvent is water, the humidity is preferably 55% or more, more preferably 70% or more, and most preferably 80% or more.
- the required humidity at the temperature at which the solvent is removed may vary.
- the gas temperature is not particularly specified, but is preferably 25 ° C or higher and 200 ° C or lower. More preferably, it is 30 ° C or higher and 100 ° C or lower. Most preferably, it is 35 ° C or higher and 80 ° C or lower.
- the temperature of the system varies greatly depending on the type of residual solvent and the mixture, and is preferably a temperature slightly below the boiling point of the residual solvent.
- the pressure for drying is not particularly limited, and any of normal pressure, pressurization, and vacuum may be used. Furthermore, you may blow.
- a third aspect of the method of the present invention is characterized in that a hydrophilic compound is included in the structure.
- the solubility of the hydrophilic compound that can be used in the present invention in water is preferably 1 mg / mL or more, more preferably 1 mg / mL or more and 200 mg / mL or less.
- the boiling point of the hydrophilic compound is preferably 100 ° C or higher, more preferably 100 ° C or higher and 1500 ° C or lower. If the degree of hygroscopicity of the hydrophilic compound (saturated water absorption per unit weight) is 1 mg / g, it is preferably 10 mg / g or more and 1000 g / g or less.
- hydrophilic compound any low molecule, synthetic polymer, or biopolymer may be used as long as the present invention can be carried out.
- glycerol ethyl N-glycolanol
- propylene glycolol butylene glycolol
- polyethylene glycolol sodium chloride, lactose, sodium polyphosphate, or sodium L-ascorbate.
- the hydrophilic compound may have a hygroscopic property.
- the hydrophilic compound may not be dissolved in water.
- water-insoluble particles obtained by treating the surface of a water-insoluble compound (eg, metal or hydrophobic polymer) with a hydrophilic or hygroscopic surface may be encapsulated in the structure!
- the content of the hydrophilic compound in the structure of the biopolymer is not particularly limited as long as the effect of the present invention can be obtained, but is generally 0.001% by weight to 10% by weight, preferably Is not less than 0.1% by weight and not more than 10% by weight, more preferably not less than 0.5% by weight and not more than 5% by weight.
- the biopolymer which is a bio-derived polymer is not particularly defined, but is preferably a protein, sugar, polysaccharide, or a derivative or salt thereof. In the case of protein, it may be any protein such as spherical or fibrous.
- the biopolymer is preferably collagen, gelatin, albumin, laminin, casein, fib mouth in, fibrin, fibronectin, vitronectin, and derivatives thereof, hyaluronic acid, and hyaluronic acid ester. More preferred are collagen, gelatin, albumin, casein, and five mouth in. Most preferred is collagen or gelatin.
- the origin of the protein is not particularly limited, and any of humans, cows, pigs, fish, and recombinants may be used. Further, as the genetically modified gelatin, for example, those described in EU1014176A2 and US6992172 can be used, but are not limited thereto.
- the form of the biopolymer is not particularly limited! /, But any of an uncrosslinked product, a physical or chemical crosslinked product, a chemically modified product, and a mixture thereof may be used.
- the biopolymer in the structure does not need to be a biopolymer alone, as long as the biopolymer is partially contained in the structure.
- the crosslinking can be performed using heat, light, a chemical crosslinking agent (condensation agent), and an enzyme.
- a chemical crosslinking agent condensation agent
- an enzyme By controlling the degree of cross-linking of biopolymers, it is possible to create various properties such as biodegradability, strength, and structure.
- the crosslinking method is not particularly limited. Examples of crosslinking methods include physical crosslinking, chemical crosslinking, thermal crosslinking, and enzyme crosslinking. Can be mentioned. Chemical or enzymatic crosslinking is preferred. Chemical cross-linking agents are generally widely used and include aldehydes such as le-daltalaldehyde and formaldehyde, carpositimide, and cyanamide. More preferred is enzyme crosslinking.
- the enzyme is not particularly limited as long as it has a cross-linking action on a protein, but preferably cross-linking with transdaltaminase and laccase, most preferably transdaltaminase. It can be performed.
- a specific example of a protein that is enzymatically cross-linked with transglutaminase is not particularly limited as long as it has a lysine residue and a glutamine residue.
- Transdaltaminase may be derived from mammals or from microorganisms. Specifically, it is derived from the Ajinomoto Co., Ltd. Activa series, which is derived from mammals sold as reagents.
- Transglutaminase for example, guinea pig liver-derived transdaltaminase from Oriental Yeast Co., Ltd., Upstate USA Inc., Biodesign International, goat-derived transdaltaminase, Usagi-derived transdaltaminase, etc. Blood coagulation factor (Factor XHIa Haematologic Technologies, Inc.).
- organic fluorine compound is preferred. More preferably, it is an organic fluorine compound having 1 to 8 carbon atoms. More preferred are organic fluorine compounds having 1 to 6 carbon atoms. More preferably, it is an organic fluorine compound having 1 to 3 carbon atoms. More preferably, the organic fluorine compound is an alcohol, a ketone, or a carboxylic acid. Particularly preferred is 1,1,1,1,3,3,3-hexafluoro-2-propanol, trifluoroethanol, hexafluoroacetone, trifluoroacetic acid, or pentafluoropropionic acid. Most preferred is 1,1,1,1,3,3,3-hexafluoro-2-propanol or trifluoroethanol. In addition, it is not necessary for the residual organic solvent to be one type. Two or more types of organic solvents may be used!
- the organic fluorine compound is not particularly limited as long as it is a fluorine-containing organic compound.
- the organic fluorine compound may be aliphatic, aromatic, saturated or unsaturated.
- a biopolymer structure can be produced by applying and drying a mixture obtained by dissolving a biopolymer in an organic solvent such as an organic fluorine compound.
- a film can be formed by applying a mixture of a drug and a biopolymer dissolved in an organic solvent such as an organic fluorine compound on a substrate and drying.
- the residual amount of the organic fluorine compound in the structure is preferably 1% or less. More preferably, it is 0.1% or less. Most preferably, it is 0.01% or less.
- the form of the structure is not particularly limited! /, But examples thereof include gels, sponges, films, nonwoven fabrics, fibers (tubes), and particles.
- the shape can be applied to any shape. Examples include a pyramid, a cone, a prism, a cylinder, a sphere, a spindle-shaped structure, and a structure created by an arbitrary mold. Preferred are a prism, a cylinder, a spindle-shaped structure, and a structure made of an arbitrary mold. More preferable are a pyramid, a cone, a prism, and a cylinder. Most preferred are prisms and cylinders.
- the size of the structure is not particularly limited, but is preferably 500 cm square or less if it is a gel, sponge, or nonwoven fabric. Preferably it is 100 cm or less. Particularly preferably, it is 50 cm or less. Most preferably, it is 10 cm or less.
- the diameter (or side) of the fiber or tube is between 1 nm and 10 cm. Preferably they are 1 nm or more and 1 cm or less. More preferably, it is 1 nm or more and 100 m. Particularly preferably, it is 1 nm or more and l ⁇ m or less. Most preferably, it is 1 nm or more and 10 nm or less.
- the length is not particularly limited, but is preferably 10 m or more and 100 m or less. More preferably, it is 100 m or more and 10 m or less. More preferably, it is 1 mm or more and 1 m or less. Most preferably, it is 1 cm or more and 30 cm or less. In the case of particles, the diameter is preferably 1 nm force, 1 mm, more preferably 10 nm to 200 ⁇ , further preferably 50 nm to 100 ⁇ m, and particularly preferably 100 nm to lO ⁇ m.
- the thickness of the structure is not particularly limited, but is preferably 1 mm or more. More preferably, it is 10 nm or more. More preferably, it is 100 nm or more. More preferably 1 m or less Above. More preferably, it is 10 m or more. Most preferably, it is 100 m or more.
- Additives may be added to the composition as necessary.
- additives include drugs, colorants, softeners, transdermal absorption promoters, moisturizers, surfactants, preservatives, fragrances, and pH adjusters.
- drugs include, for example, anticancer drugs (for example, paclitaxel, topotecin, taxotere, 5-fluorouracil), immunosuppressants (for example, rapamycin, tacrolimus, cyclosporine), anti-inflammatory drugs, antithrombotic drugs, anti-thrombotic drugs, Mental agents, antidepressants, antioxidants, antiallergic agents, growth factors, hormones, supplement ingredients, cosmetic ingredients.
- anticancer drugs for example, paclitaxel, topotecin, taxotere, 5-fluorouracil
- immunosuppressants for example, rapamycin, tacrolimus, cyclosporine
- anti-inflammatory drugs for example, antithrombotic drugs, anti-thrombotic drugs, Mental agents, antidepressants, antioxidants, antiallergic agents, growth factors, hormones, supplement ingredients, cosmetic ingredients.
- Applications are not particularly limited! /, But are percutaneous absorption agents, topical treatments, implants, oral treatments, cosmetics, supplements, foods, and color materials. Preferred are transdermal absorption agents, local therapeutic agents, oral therapeutic agents, and cosmetics. More preferred are transdermal absorption agents, topical therapeutic agents, implants, and oral therapeutic agents. Most preferred are transdermal absorption agents and topical treatment agents.
- HFIP solution containing acid-treated gelatin (20%, PSP gelatin, manufactured by Futsubishi) and paclitaxel (1 mg / mL) was applied onto a polypropylene substrate (application thickness: 1 mm).
- the film was allowed to stand under various solvent removal conditions, or air-dried or vacuum-dried to obtain a paclitaxel-encapsulated gelatin film.
- the gelatin film was immersed in methanol for a while to extract residual HFIP.
- a paclitaxel-encapsulated gelatin film mixed with 1% glycerin was similarly prepared, dried at 60 ° C. and 95%, and the residual amount of HFIP was similarly determined.
- the residual HFIP amount was 25.7%.
- the amount of residual HFIP decreases compared to natural drying. 18%.
- water was added to the air that is, the solvent was removed at 80% humidity
- the amount of residual HFIP decreased significantly, decreasing to 0.2% in 72 hours and decreasing to 0.002% in 168 hours.
- the humidity was 95% at 50 ° C or 80% at 60 ° C, it was less than 0.001% in 72 hours.
- the amount of residual HFIP could be reduced to about 1 / 10,000 of the amount of HFIP in the vacuum-dried sample by simultaneous drying. It can be said that the amount of HFIP was efficiently reduced by adding a large amount of water vapor to the gas when removing HFIP.
- HFIP could be similarly removed from the albumin film (prepared from a 10% solution) by this operation.
- Example 2 Stability of paclitaxel inside the film
- Paclitaxel-encapsulated gelatin film prepared in Example 1 can be treated with lactinase to decompose latin and extract with ethyl acetate to recover paclitaxel quantitatively. It was.
- HFIP which is a good solvent for paclitaxel, was removed, it was possible to prevent paclitaxel from flowing out of the gelatin film.
- the gelatin film prepared from HFIP has a problem that the edge of the film warps during drying. By using the present invention, the warpage of the film can be improved.
- An HFIP solution containing acid-treated gelatin (10% or 20%, PSP gelatin, manufactured by Futsubishi) and paclitaxel (1 mg / mL) was coated on a polypropylene substrate (size: 20 cm x 20 cm, coated) Thickness: 1 mm). The film was immersed in deionized water at 4 ° C or 20 ° C for 1 hour. After the crosslinking and washing operations, natural drying was performed for 1 day to obtain a paclitaxel-encapsulated gelatin film.
- the gelatin film was dipped in methanol for extraction of residual HFIP.
- the amount of HFIP decreased in the same way even when the washing operation was performed at 20 ° C (Table 2).
- the removal of HFIP from gelatin film is not sufficient by ordinary vacuum drying, and it can be said that the water washing operation is effective for removing gelatin structure strength and other HFIP.
- Acid-treated gelatin (20% PSP gelatin, manufactured by Futsubi), paclitaxel (1 mg / mL), and a predetermined amount of glycerol or activa TG-S (Ajinomoto Co., Inc. composition transglutaminase: 1%, sodium polyphosphate: An HFIP solution containing 5%, sodium pyrophosphate: 5% L-socorbate: 0.5%, lactose: 88.5%) was applied onto a polypropylene substrate to form a film (application thickness: 1 mm). The film was allowed to stand under various solvent removal conditions and then air-dried for 3 days to obtain a paclitaxel-encapsulated gelatin film.
- the gelatin Rum was immersed in methanol for a while to extract residual HFIP.
- HFIP could be similarly removed from the albumin film (prepared from a 10% solution) by this operation.
- the paclitaxel-encapsulated gelatin film prepared in Example 4 was treated with lactinase to decompose latin and extracted with ethyl acetate, so that paclitaxel could be quantitatively recovered.
- HFIP which is a good solvent for paclitaxel
- gelatin films made from HFIP were able to improve the warpage of the film by using the force S, the present invention, which had the problem of warping the edges of the film during drying.
- a PBS solution containing gelatin PSK gelatin, Futsubi
- dartalaldehyde GA
- mold 5 x 10 cm x 4 mm
- GA dartalaldehyde
- the gel was immersed in a 50 mM glycine solution (lOO mL) at 37 ° C. and allowed to stand for 1 hour.
- the sample was further immersed in deionized water (100 mL) at 37 ° C and allowed to stand for 1 hour (immersion twice in deionized water).
- An HFIP solution containing paclitaxel (concentration of paclitaxel: 1.5%, 0.7%, volume: 50 L or 100 U) was added to the sponge at room temperature to swell the gelatin sponge, so that paclitaxel was impregnated into the gelatin sponge.
- the paclitaxel-encapsulated gelatin sponge was allowed to stand for 3 days under the prescribed conditions (temperature: 50 ° C, humidity; 95%) and then naturally dried for 1 day to obtain a paclitaxel-encapsulated gelatin sponge.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/515,501 US20100075392A1 (en) | 2006-11-21 | 2007-11-21 | Method for removing organic solvent |
JP2008545436A JP5260304B2 (ja) | 2006-11-21 | 2007-11-21 | 有機溶媒の除去方法 |
EP07832307.8A EP2093248B1 (en) | 2006-11-21 | 2007-11-21 | Method for removing organic solvent |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006-313956 | 2006-11-21 | ||
JP2006313956 | 2006-11-21 | ||
JP2007-030124 | 2007-02-09 | ||
JP2007030124 | 2007-02-09 | ||
JP2007-030123 | 2007-02-09 | ||
JP2007030123 | 2007-02-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008062840A1 true WO2008062840A1 (en) | 2008-05-29 |
Family
ID=39429770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/072577 WO2008062840A1 (en) | 2006-11-21 | 2007-11-21 | Method for removing organic solvent |
Country Status (4)
Country | Link |
---|---|
US (1) | US20100075392A1 (ja) |
EP (2) | EP3189833A1 (ja) |
JP (2) | JP5260304B2 (ja) |
WO (1) | WO2008062840A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010026760A1 (ja) * | 2008-09-03 | 2010-03-11 | 富士フイルム株式会社 | 生理活性成分を安定に封入した組成物 |
JP2010051438A (ja) * | 2008-08-27 | 2010-03-11 | Fujifilm Corp | キトサンと生体由来高分子の構造体における有機溶媒の除去方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008026644A1 (fr) | 2006-08-29 | 2008-03-06 | Fujifilm Corporation | Matrice hydrophile ayant un composé faiblement soluble dans l'eau scellé à l'intérieur de celle-ci et procédé pour produire celle-ci |
CN107744721A (zh) * | 2017-10-25 | 2018-03-02 | 安徽华创环保设备科技有限公司 | 一种用于废气除硫过程的监控系统 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4721915B1 (ja) * | 1968-04-10 | 1972-06-20 | ||
JPS5230884A (en) * | 1974-10-07 | 1977-03-08 | Hoechst Ag | Process for preparing mold goods of plastic material comprising chemically modified protein |
EP1014176A2 (en) | 1998-12-23 | 2000-06-28 | Fuji Photo Film B.V. | Silver halide emulsions containing recombinant gelatin-like proteins |
JP2002027283A (ja) | 2000-07-10 | 2002-01-25 | Matsushita Electric Ind Co Ltd | 水平pll回路 |
JP2002531182A (ja) | 1998-12-03 | 2002-09-24 | ネアーリッヒ、ミヒャエル | 多孔質複合マトリックス並びにその製造方法及び使用法 |
JP2002347107A (ja) * | 2001-05-22 | 2002-12-04 | Inst Of Physical & Chemical Res | 延伸フィルムおよびそれを用いた細胞培養基材 |
JP2004532802A (ja) | 2000-10-18 | 2004-10-28 | ヴァージニア コモンウェルス ユニバーシティ インテレクチュアル プロパティー ファンデーション | 薬剤送達および細胞被包における電気処理 |
JP2004321484A (ja) | 2003-04-24 | 2004-11-18 | Sangaku Renkei Kiko Kyushu:Kk | 医療用高分子ナノ・マイクロファイバー |
WO2004108810A1 (de) * | 2003-06-06 | 2004-12-16 | Humanautocell Gmbh | Matrix, zellimplantat, verfahren zu deren herstellung und deren verwendung |
US6992172B1 (en) | 1999-11-12 | 2006-01-31 | Fibrogen, Inc. | Recombinant gelatins |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5294249A (en) * | 1987-03-27 | 1994-03-15 | Luisi Pier L | Blendpolymers |
US5919906A (en) * | 1998-11-05 | 1999-07-06 | Eastman Kodak Company | Protease produced gelatin |
US7842780B2 (en) * | 2003-01-07 | 2010-11-30 | Trustees Of Tufts College | Silk fibroin materials and use thereof |
WO2008026644A1 (fr) * | 2006-08-29 | 2008-03-06 | Fujifilm Corporation | Matrice hydrophile ayant un composé faiblement soluble dans l'eau scellé à l'intérieur de celle-ci et procédé pour produire celle-ci |
-
2007
- 2007-11-21 EP EP17153266.6A patent/EP3189833A1/en not_active Withdrawn
- 2007-11-21 US US12/515,501 patent/US20100075392A1/en not_active Abandoned
- 2007-11-21 WO PCT/JP2007/072577 patent/WO2008062840A1/ja active Application Filing
- 2007-11-21 EP EP07832307.8A patent/EP2093248B1/en active Active
- 2007-11-21 JP JP2008545436A patent/JP5260304B2/ja active Active
-
2013
- 2013-04-24 JP JP2013090941A patent/JP5612154B2/ja active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4721915B1 (ja) * | 1968-04-10 | 1972-06-20 | ||
JPS5230884A (en) * | 1974-10-07 | 1977-03-08 | Hoechst Ag | Process for preparing mold goods of plastic material comprising chemically modified protein |
JP2002531182A (ja) | 1998-12-03 | 2002-09-24 | ネアーリッヒ、ミヒャエル | 多孔質複合マトリックス並びにその製造方法及び使用法 |
EP1014176A2 (en) | 1998-12-23 | 2000-06-28 | Fuji Photo Film B.V. | Silver halide emulsions containing recombinant gelatin-like proteins |
US6992172B1 (en) | 1999-11-12 | 2006-01-31 | Fibrogen, Inc. | Recombinant gelatins |
JP2002027283A (ja) | 2000-07-10 | 2002-01-25 | Matsushita Electric Ind Co Ltd | 水平pll回路 |
JP2004532802A (ja) | 2000-10-18 | 2004-10-28 | ヴァージニア コモンウェルス ユニバーシティ インテレクチュアル プロパティー ファンデーション | 薬剤送達および細胞被包における電気処理 |
JP2002347107A (ja) * | 2001-05-22 | 2002-12-04 | Inst Of Physical & Chemical Res | 延伸フィルムおよびそれを用いた細胞培養基材 |
JP2004321484A (ja) | 2003-04-24 | 2004-11-18 | Sangaku Renkei Kiko Kyushu:Kk | 医療用高分子ナノ・マイクロファイバー |
WO2004108810A1 (de) * | 2003-06-06 | 2004-12-16 | Humanautocell Gmbh | Matrix, zellimplantat, verfahren zu deren herstellung und deren verwendung |
Non-Patent Citations (1)
Title |
---|
See also references of EP2093248A4 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010051438A (ja) * | 2008-08-27 | 2010-03-11 | Fujifilm Corp | キトサンと生体由来高分子の構造体における有機溶媒の除去方法 |
WO2010026760A1 (ja) * | 2008-09-03 | 2010-03-11 | 富士フイルム株式会社 | 生理活性成分を安定に封入した組成物 |
Also Published As
Publication number | Publication date |
---|---|
EP2093248B1 (en) | 2017-03-29 |
EP2093248A1 (en) | 2009-08-26 |
EP3189833A1 (en) | 2017-07-12 |
JP5260304B2 (ja) | 2013-08-14 |
US20100075392A1 (en) | 2010-03-25 |
JP5612154B2 (ja) | 2014-10-22 |
JP2013139487A (ja) | 2013-07-18 |
EP2093248A4 (en) | 2013-05-08 |
JPWO2008062840A1 (ja) | 2010-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tavakoli et al. | A multifunctional nanocomposite spray dressing of Kappa-carrageenan-polydopamine modified ZnO/L-glutamic acid for diabetic wounds | |
ES2645089T3 (es) | Procedimiento para la limpieza de colágeno marino, así como su transformación en esponjas porosas | |
JP5752123B2 (ja) | キトサン組織被覆材 | |
JP4459543B2 (ja) | 徐放性ハイドロゲル製剤 | |
WO2008072379A1 (ja) | 修飾された生体高分子の製造方法及び生体高分子の架橋方法 | |
JP2010053080A (ja) | キトサンとコラーゲンを含む構造体 | |
JP5612154B2 (ja) | 有機溶媒の除去方法 | |
JP2001009020A (ja) | 低臭性で機械的特性が改善された海原産コラーゲン含有コラーゲン製品、及び、化粧又は医薬の組成物又は製品としてのその使用 | |
KR20140037271A (ko) | 유착 방지용 의료용 재료 및 그 제조 방법 | |
JPWO2009041627A1 (ja) | 膨潤性架橋ヒアルロン酸粉末及びその製造方法 | |
JP2010540486A (ja) | 基材表面からの水不溶性物質の除去方法 | |
Milan et al. | Influence of blend ratio and mangosteen extract in chitosan/collagen gels and scaffolds: Rheological and release studies | |
JPWO2007083672A1 (ja) | 繊維処理剤、繊維処理方法、この繊維処理剤により処理された繊維および布帛 | |
CN107715181A (zh) | 一种可生物降解的组织工程皮肤支架的制备方法 | |
TWI542365B (zh) | 可溶性膠原蛋白及其製備方法 | |
Siaghi et al. | Luteolin-incorporated fish collagen hydrogel scaffold: An effective drug delivery strategy for wound healing | |
Xiang et al. | Biological scaffold as potential platforms for stem cells: Current development and applications in wound healing | |
JP4124745B2 (ja) | キトサン分散液及びその製造方法並びにキトサン膜の製造方法 | |
KR100605382B1 (ko) | 멍게 또는 미더덕-유래 셀룰로오스 막을 포함하는 피부상처 보호막 및 골형성 유도막 | |
Yamauchi et al. | Enzymatic degradation of keratin films and keratin fibers prepared from human hair | |
JP2007001963A (ja) | 吸水性の高いキトサンスポンジの製造方法 | |
WO2008072378A1 (ja) | 合成高分子表面の生体高分子によるコーティング方法 | |
Din et al. | Temperature and pH-sensitive chitosan-collagen hydrogels for antimicrobial and wound healing applications | |
JP2010051438A (ja) | キトサンと生体由来高分子の構造体における有機溶媒の除去方法 | |
CN112842931A (zh) | 一种动物胶原蛋白冻干球、化妆品套装及制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07832307 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008545436 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12515501 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2007832307 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007832307 Country of ref document: EP |